“The earlier cognitive impairment is detected the sooner and more efficiently the brain can be protected. The Altoida technology will be applicable in the direct care of patients and for research to help provide the next generation of therapeutic products. A test that will be easy to obtain, simple to perform, readily available, affordable, instantly diagnostic, reliable and can establish efficaciousness is a remarkable breakthrough in medicine”, Charles Neblett, M.D., Neurosurgeon - Baylor College of Medicine and Consultant/Medical Director at McNair Medical Institute, Houston TX

“We have been testing the Altoida technology since June 2018 in specific clinical settings and the technology looks extremely promising. It is exactly what we have been looking for to improve our day to day routine, since the prevention of cognitive impairment in persons at risk of Alzheimer’s Disease/MCI and therefore prolonging the onset of AD, is much more important than treating already advanced patients. Altoida cognitive assessment technology for everyday functions will assist clinicians in identifying these risks in a reliable and gamified way.” said Dr. med. Henry Perschak Hirslanden AG, Klinik Zürich, Switzerland

“Diagnosis of an individual at risk for Alzheimer’s disease has been the biggest challenge in the field of Alzheimer’s disease and the Altoida, digital biomarker technology will provide us with an innovative tool to detect the onset of Alzheimer’s disease in a reliable and gamified fashion.” – Dr. Namrata Das MD, MPH, Center for BrainHealth, The University of Texas at Dallas, who has been studying Altoida’s technology for the past year.

“Developing enhanced methods to objectively evaluate cognitive function is a critical component of the next generation digital medicine – a component that is required to not only advance the basic research in neurodegenerative disease but also one that is required for the development of improved clinical interventions. Altoida’s novel approach to developing digital biomarkers of cognitive function will promote the elaboration of specific ‘biotypes’ of neurodegenerative disease. Understanding neurodegenerative biotypes will dramatically improve our ability to conduct a differential diagnosis at the primary care level. Improved diagnostics will provide healthcare professionals with the key information necessary to precisely adapt clinical interventions to personalize the patient’s cognitive care. This will ultimately lead to improved outcomes of care and to reduced healthcare costs.” Dr. Walter Greenleaf Ph.D., a neuroscientist and Distinguished Visiting Scholar working at the Stanford University Virtual Human Interaction Lab

"As the world’s effort to introduce meaningful therapies for Alzheimer’s disease inches closer and closer to success, it is clear that the greatest benefit will come to those whose disease is detected at a very early stage,” said Jonathan L. Liss, MD, Director at Columbus Memory Center and Founder of Columbus Memory Project who has been studying Altoida’s technology since September 2018. “The Altoida technology offers an ingenious way in which to detect early disease and track progression without prolonged cognitive testing, tissue sampling, or radiologic intervention. The Altoida technology is a welcome advancement to the field of cognitive health."